Keros Therapeutics Announces Final Results of Tender Offer
MWN-AI** Summary
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced the final results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock at a purchase price of $17.75 per share, totaling approximately $194.4 million. The tender offer, which expired on November 18, 2025, was part of a broader $375 million capital return program initiated by the company.
The company received an overwhelming response, with a total of 17,712,262 shares tendered, exceeding the maximum number of shares set for repurchase. As a result, Keros accepted shares on a pro rata basis, applying a proration factor of approximately 62.30%. Consequently, the shares purchased account for about 35.91% of Keros’ outstanding common stock as of the expiration date.
Payment for the accepted shares will be made using Keros' existing cash reserves, and all unaccepted shares will be returned to the respective shareholders. Shareholders seeking more information can contact MacKenzie Partners, Inc., the information agent, or Goldman Sachs & Co. LLC, the dealer manager for the tender offer.
Keros Therapeutics focuses on developing innovative therapeutics targeting disorders associated with dysfunctional signaling within the TGF-ß protein family. Their lead candidate, KER-065, is aimed at treating neuromuscular diseases such as Duchenne muscular dystrophy, while another key product, elritercept, targets cytopenias related to myelodysplastic syndrome and myelofibrosis.
This summary reflects Keros' commitment to returning capital to its shareholders while continuing to advance its clinical pipeline, although as with all forward-looking statements, outcomes are subject to various risks and uncertainties that could result in actual results differing from expectations.
MWN-AI** Analysis
Keros Therapeutics has recently concluded a significant cash tender offer, repurchasing 10,950,165 shares of its common stock priced at $17.75 per share, amounting to approximately $194.4 million. With nearly 17.7 million shares tendered, the company had to implement a pro-rata allocation, satisfying about 62.3% of the applications due to the overwhelming demand. This buyback represents approximately 35.91% of Keros' total outstanding shares, signaling a substantial commitment to returning value to shareholders amid ongoing capital return strategies.
From a market perspective, Keros’ decision to execute a tender offer can be interpreted as a demonstration of management's confidence in the company's long-term prospects. The repurchase not only supports the stock price but also indicates that the company believes its shares are undervalued. Such actions often bolster investor sentiment and can lead to upward price movements in the stock.
Investors should consider Keros' strategic focus on developing innovative treatments for neuromuscular diseases and cytopenias, which positions the company at the forefront of promising biopharmaceutical advancements. KER-065 and elritercept’s progress in clinical trials will be critical to monitor, as successful outcomes could substantially increase Keros' market valuation.
However, while the tender offer is positive news, potential investors should also be cautious of inherent risks associated with clinical-stage companies, including fluctuating market conditions and the uncertainties associated with drug development. It is advisable for investors to conduct a thorough analysis of Keros’ financial health, including its last quarterly results and cash flow situation reported on November 5, 2025.
Overall, with the tender offer concluded, Keros Therapeutics could present an attractive opportunity for investors looking for exposure in the biotech sector, but it’s essential to assess the broader context of its market performance and developments in the drug pipeline.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company’s previously announced $375 million capital return program.
Based on the final count by Computershare Trust Company, N.A., the depositary for the Tender Offer (the “Depositary”), a total of 17,712,262 shares of Keros common stock were validly tendered and not validly withdrawn, which includes shares that were tendered through notice of guaranteed delivery.
In accordance with the terms and conditions of the Tender Offer, the Company accepted for purchase a total of 10,950,165 shares, for an aggregate purchase price of approximately $194.4 million, excluding fees and expenses related to the Tender Offer. Because more than 10,950,165 shares were tendered in the Tender Offer, shares were accepted for purchase on a pro rata basis, except for conditional tenders that will automatically be regarded as withdrawn if the condition was not satisfied. Keros has been informed by the Depositary that the final proration factor for the Tender Offer is approximately 62.30%. The shares purchased represent approximately 35.91% of Keros’ outstanding common stock as of November 18, 2025.
The Depositary will promptly pay for all shares accepted for purchase pursuant to the Tender Offer using the Company’s existing cash and cash equivalents and return all other shares tendered and not purchased.
Stockholders with questions about the Tender Offer may contact MacKenzie Partners, Inc., the information agent for the Tender Offer, toll-free at (800) 322-2885, at (212) 929-5500 or in writing at 7 Penn Plaza, New York, NY 10001. Stockholders may also contact Goldman Sachs & Co. LLC, the dealer manager for the Tender Offer, at (212) 902-8556.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,” “intention,” “potential” and “will” or similar expressions are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: developments or changes in economic or market conditions; developments or changes in the securities markets, developments or changes in Keros’ business, financial condition or cash flows, and other risks detailed in Keros’ reports filed with the Securities and Exchange Commission (the “SEC”), including its quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025, and its other documents subsequently filed with or furnished to the SEC. Keros disclaims any intent or obligation to update these forward-looking statements.
Contacts
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Media Contact:
Mahmoud Siddig / Adam Pollack / Brooks Hussey
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
FAQ**
How has the cash tender offer by Keros Therapeutics Inc. KROS impacted the overall market perception of the company following the repurchase of 10,950,165 shares at $17.75 each, as announced on November 20, 2025?
What strategies does Keros Therapeutics Inc. KROS plan to implement moving forward after concluding its $375 million capital return program, and how could these affect investor confidence?
Given the pro-rata acceptance rate of approximately 62.30% in the recent tender offer, what implications does this have for the remaining investors in Keros Therapeutics Inc. KROS, and how might it influence their future decisions?
In light of Keros Therapeutics Inc. KROS's focus on developing therapeutics linked to TGF-ß proteins, which upcoming clinical trial results could be most significant for potential investors post-tender offer?
**MWN-AI FAQ is based on asking OpenAI questions about Keros Therapeutics Inc. (NASDAQ: KROS).
NASDAQ: KROS
KROS Trading
-9.0% G/L:
$10.82 Last:
298,058 Volume:
$11.49 Open:
